RXi licenses RNAi self-delivery technology
This article was originally published in Scrip
RXi Pharmaceuticals has exercised its option to an exclusive worldwide licence to novel technologies from Advirna to enable in vivo delivery of RNAi therapeutics. Terms of the agreement were not disclosed.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.